18 Nov 2020

Lonza Expands Highly Potent Drug Product Development and Manufacturing Capabilities

Downloads

  • Highly potent capability implemented in Lonza-Tampa (US) product development labs
  • Highly potent capable Gerteis roller compactor installed for improved continuous dry granulation

Quote from Christian Dowdeswell, Vice President and Global Head of Commercial Development, Small Molecules, Lonza:

"Our customers look to Lonza to meet their challenge of accelerating timelines to clinic and market. In response, we strive for seamless service provision across our drug substance and drug product development and manufacturing network. These new investments ensure that we have capabilities that meet our customers' needs and standardizes state-of-the-art continuous dry granulation across Lonza's solid oral dose manufacturing network. This gives us more flexibility in development as well as facilitating more rapid scale-up."

Quote from Robert Beland, Managing Director, Lonza Tampa:

"The ability to safely and efficiently handle HPAPI is increasingly critical to effectively partner with our customers, especially those focused on cancer therapies. The new roller compactor complements the capabilities of both the Tampa site and our overall network for product development and manufacturing based on HPAPI."

Tampa, USA, 18 November 2020 – Lonza has announced additional investments in its oral drug product development and manufacturing capabilities at its Tampa FL site. Capability for formulation development has been enhanced with the upgrade of drug product development laboratories for highly potent material handling. Dry granulation processing has been expanded and standardized with the addition of Gerteis roller compaction equipment. The new roller compactor will be equipped with high containment and adds to Lonza’s integrated highly potent API (HPAPI) value chain across drug substance, particle engineering and specialized drug product.

The containment capability of the new roller compaction unit complements Lonza’s leading capabilities in HPAPI processing across its site network in the US and Europe. The Visp, Switzerland site has one of the world’s largest capacity for HPAPI development and manufacturing. Contained particle engineering, using either jet milling or spray dry processing, and specialized oral solid or parenteral drug product capabilities are also available within the network.

Lonza has invested more than $15M to expand and upgrade the Tampa site capabilities over the last two years. The new roller compaction equipment complements previously made HPAPI processing investments inclusive of a new sampling and dispensing suite, a dedicated suite for product development, and two new product manufacturing suites.